Description

DBCO-PEG4-Val-Cit-PAB-MMAF consists a cleavable 4 unit PEG ADC linker (DBCO-PEG4-Val-Cit-PAB) and a potent tubulin polymerization inhibitor (MMAF). DBCO-PEG4-Val-Cit-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs)[1]. DBCO-PEG4-Val-Cit-PAB-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.–20°C (Powder, stored under nitrogen)-Applications-Cancer-programmed cell death-Formula-C88H126N12O20-Citation–References-[1]Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.-CASNumber-2244602-23-9-MolecularWeight-1672.01-Compound Purity-99.99-SMILES-C[C@@H](C(N[C@H](C(O)=O)CC1=CC=CC=C1)=O)[C@H]([C@@](CCC2)([H])N2C(C[C@@H](OC)[C@@]([C@@H](C)CC)([H])N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(OCC3=CC=C(NC([C@H](CCCNC(N)=O)NC([C@@H](NC(CCOCCOCCOCCOCCNC(CCC(N4C(C=CC=C5)=C5C#CC(C=CC=C6)=C6C4)=O)=O)=O)C(C)C)=O)=O)C=C3)=O)=O)=O)=O)OC-Research_Area-Cancer-Solubility-DMSO : 250 mg/mL (ultrasonic)-Target-Drug-Linker Conjugates for ADC-Isoform-Auristatin-Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related